Chemosensitization of Fluconazole Resistance in Saccharomyces cerevisiae and Pathogenic Fungi by a d -Octapeptide Derivative
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Hyperexpression of the Saccharomyces cerevisiae multidrug ATP-binding cassette (ABC) transporter Pdr5p was driven by the pdr1-3 mutation in the Pdr1p transcriptional regulator in a strain (AD/PDR5 + ) with deletions of five other ABC-type multidrug efflux pumps. The strain had high-level fluconazole (FLC) resistance (MIC, 600 μg ml −1 ), and plasma membrane fractions showed oligomycin-sensitive ATPase activity up to fivefold higher than that shown by fractions from an isogenic PDR5 -null mutant (FLC MIC, 0.94 μg ml −1 ). In vitro inhibition of the Pdr5p ATPase activity and chemosensitization of cells to FLC allowed the systematic screening of a 1.8-million-member designer d- octapeptide combinatorial library for surface-active Pdr5p antagonists with modest toxicity against yeast cells. Library deconvolution identified the 4-methoxy-2,3,6-trimethylbenzensulfonyl-substituted d- octapeptide KN20 as a potent Pdr5p ATPase inhibitor (concentration of drug causing 50% inhibition of enzyme activity [IC 50 ], 4 μM) which chemosensitized AD/PDR5 + to FLC, itraconazole, and ketoconazole. It also inhibited the ATPase activity of other ABC transporters, such as Candida albicans Cdr1p (IC 50 , 30 μM) and Cdr2p (IC 50 , 2 μM), and chemosensitized clinical isolates of pathogenic Candida species and S. cerevisiae strains that heterologously hyperexpressed either ABC-type multidrug efflux pumps, the C. albicans major facilitator superfamily-type drug transporter Ben R p, or the FLC drug target lanosterol 14α-demethylase (Erg11p). Although KN20 also inhibited the S. cerevisiae plasma membrane proton pump Pma1p (IC 50 , 1 μM), the peptide concentrations required for chemosensitization made yeast cells permeable to rhodamine 6G. KN20 therefore appears to indirectly chemosensitize cells to FLC by a nonlethal permeabilization of the fungal plasma membrane.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Antifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Prasad, R., De Wergifosse, P., Goffeau, A., & Balzi, E. (1995) · Current Genetics · doi:10.1007/bf00352101 · Cited by 486 · cited 6×
“Those most extensively characterized include C. albicans CDR1 (47), CDR2 (52), and BENR (6, 24, 53); C. glabrata CgCDR1 (51) and PDH1 or CgCDR2 (38, 50, 60); C. krusei ABC1 and ABC2 (28); and Aspergillus AfuMDR1, AfuMDR2, AflMDR1, AtrA, and AtrB (12, 58).”
Self-citationBalzi, E., Wang, M., Leterme, S., Van Dyck, L., & Goffeau, A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42155-7 · Cited by 447
Self-citationSanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337 · cited 4×
“glabrata CgCDR1 (51) and PDH1 or CgCDR2 (38, 50, 60); C.”
InfluentialPotent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans
Marchetti, O., Moreillon, P., Glauser, M. P., Bille, J., & Sanglard, D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2373-2381.2000 · Cited by 252
Sanglard, D., Ischer, F., & Bille, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1174-1183.2001 · Cited by 247
Francis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232 · cited 1×
“Combination therapy with different classes of antifungal agents has long been proposed by clinicians to enhance efficacy and to reduce toxic effects in the treatment of refractory fungal infections (20), but the suggestion that inhibitors of fungal drug efflux pathways could serve as antifungal chemosensitizers is mor…”
Background
Cited by
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Self-citationSagatova, A. A., Keniya, M. V., Wilson, R. K., Monk, B. C., & Tyndall, J. D. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00925-15 · Cited by 210
Self-citationCandida albicans drug resistance—Another way to cope with stress
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Tanabe, K., Niimi, M., & Monk, B. C. (2007) · Microbiology · doi:10.1099/mic.0.2007/010405-0 · Cited by 208
“, 2007) but also provides a system to screen for pump inhibitors that chemosensitize the strains overexpressing pumps to fluconazole (Monk et al., 2002; Niimi et al., 2004; Schuetzer-Muehlbauer et al., 2003).”
BackgroundSelf-citationLamping, E., Monk, B. C., Niimi, K., Holmes, A. R., Tsao, S., Tanabe, K., Niimi, M., Uehara, Y., & Cannon, R. D. (2007) · Eukaryotic Cell · doi:10.1128/ec.00091-07 · Cited by 190
“pumps to FLC was carried out as described previously (40).”
BackgroundMethodSelf-citationTargeting Efflux Pumps to Overcome Antifungal Drug Resistance
Holmes, A. R., Cardno, T. S., Strouse, J. J., Ivnitski-Steele, I., Keniya, M. V., Lackovic, K., Monk, B. C., Sklar, L. A., & Cannon, R. D. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0050 · Cited by 156
Self-citationNiimi, K., Maki, K., Ikeda, F., Holmes, A. R., Lamping, E., Niimi, M., Monk, B. C., & Cannon, R. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1148-1155.2006 · Cited by 134
“0) was used for MIC determinations (22) because RPMI medium did not support the growth of the S.”
BackgroundMethodInfluentialHolmes, A. R., Keniya, M. V., Ivnitski-Steele, I., Monk, B. C., Lamping, E., Sklar, L. A., & Cannon, R. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05706-11 · Cited by 106
“Microplate checkerboard assays of the chemosensitization of yeast strains to FLC by various inhibitor compounds were undertaken as described previously (33).”
BackgroundMethodSelf-citationLamping, E., Ranchod, A., Nakamura, K., Tyndall, J. D. A., Niimi, K., Holmes, A. R., Niimi, M., & Cannon, R. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01095-08 · Cited by 100
“carried out as described previously (28).”
MethodSelf-citationNovel Antifungal Mechanism of Resveratrol: Apoptosis Inducer in Candida albicans
Lee, J., & Lee, D. G. (2015) · Current Microbiology · doi:10.1007/s00284-014-0734-1 · Cited by 71
Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance
Niimi, M., Niimi, K., Takano, Y., Holmes, A. R., Fischer, F. J., Uehara, Y., & Cannon, R. D. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh456 · Cited by 69
“cerevisiae for the functional analysis of efflux pumps(26,43) and for screening for pump inhibitors.(44,45)”
BackgroundSelf-citationHolmes, A. R., Tsao, S., Ong, S., Lamping, E., Niimi, K., Monk, B. C., Niimi, M., Kaneko, A., Holland, B. R., Schmid, J., et al. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05357.x · Cited by 68
“Consistent segregation of the 1473/1474 SNP pair in separately cloned alleles of CDR2 with differential susceptibility to FLC In order to determine whether differential function of CDR2 alleles occurred in clinical isolates as well as in the laboratory strain ATCC 10261, each allele of CDR2 from the isogenic strains T…”
BackgroundMethodInfluentialSelf-citationCoprisin-induced antifungal effects in Candida albicans correlate with apoptotic mechanisms
Lee, J., Hwang, J.-S., Hwang, I.-S., Cho, J., Lee, E., Kim, Y., & Lee, D. G. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.03.012 · Cited by 64
“To investigate cytochrome c release from the mitochondria, the mitochondria were isolated [16].”
BackgroundHolbrook, S. Y. L., Garzan, A., Dennis, E. K., Shrestha, S. K., & Garneau-Tsodikova, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.030 · Cited by 51
Milbemycins: More than Efflux Inhibitors for Fungal Pathogens
Silva, L. V., Sanguinetti, M., Vandeputte, P., Torelli, R., Rochat, B., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02040-12 · Cited by 49
“Several studies already established that this family of substances inhibit fungal ABC transporters (20, 21, 50); however, it is the first time, to our knowledge, that this is demonstrated for oxim derivatives.”
BackgroundZhang, T., & Chen, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091858 · Cited by 37
“Isolation of mitochondria were performed according to the method of Niimi with slight modifications [44].”
MethodCandida Efflux ATPases and Antiporters in Clinical Drug Resistance
Prasad, R., Rawal, M. K., & Shah, A. H. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-25304-6_15 · Cited by 30
Metadata
- Authors
- Niimi, K., Harding, D. R. K., Parshot, R., King, A., Lun, D. J., Decottignies, A., Niimi, M., Lin, S., Cannon, R. D., Goffeau, A., & Monk, B. C.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2004-04
- Volume
- 48
- Issue
- 4
- Pages
- 1256-1271
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2037368475
- Cited by
- 114
- References
- 14
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.